KRAS and neoplasm: According to a recent report, the ORR, DCR and mPFS were determined to be 35.4%, 91.7% and 9.3 months respectively, all remarkably better than historical data.278 Of note, the response rate in KRAS responders (≥ 90% decrease in KRAS mutant allele frequency in circulating tumor DNA (ctDNA) after 1 cycle of treatment) was considerably higher than that of KRAS nonresponders.